Unversity of Nottingham signed strategic partnership with Tasly Group

The University of Nottingham and China’s Tasly Group (China's largest pharmaceutical companies - the world leader in creating modern drugs from ancient natural chinese remedies) signed a wide-ranging new strategic partnership. This deal promises to combine areas of expertise which will stimulate further natural drug discovery efforts and may bring economic benefits to the East Midlands

Senior executives from Tasly Group were among some of the world’s foremost experts on Chinese medicine who gathered on University Park campus in Nottingham for the 8th Meeting of the Consortium for Globalisation of Chinese Medicine (CGCM). This event was held outside Asia for the first time, recognising the University’s long-term commitment to research into Chinese medicine.

“Traditional Chinese medicine embodies a sophisticated system of diagnosis, prescription and treatment with vast potential for pharmacology. This exciting agreement will let us work together to isolate compounds and develop more effective therapies for mainstream use.”

Tasly Group Vice-President Dr Henry Sun said: “Tasly Group would like to collaborate with The University of Nottingham at all levels for research and development, regulatory approval, and commercialisation. There are many ways in which our experience can contribute to The University of Nottingham’s ongoing research in traditional Chinese medicine.

In China, over 15 years of development at Tasly Group has applied pharmaceutical industry techniques to traditional medicine. It has become a high-tech firm whose scope includes modern traditional Chinese medicine, chemical medicine, biological medicine, vaccines, healthcare products, and functional food, covering research and development, planting, manufacturing, and distribution.

Over 75,000 formulations are reportedly in use in traditional Chinese medicine, consisting of combinations of more than 5,000 single compounds. While there is a strong belief that many of these formulations have therapeutic value, clinical and scientific evidence to support the claims is often poorly documented or seriously lacking.

In its research, Tasly Group has already isolated over 16,000 purified single compounds and 10,000 fractional extracts. Those purified compounds and fractional mixtures are extracted from 240 of the 300 most frequently used herbs. Around 130 Chinese medicine projects are in early and later stages of research, development and commercialisation covering anti-infective, anti-cancer, cardiovascular, endocrine, gastro-intestinal, diabetes, cholesterol control, and women’s health medicine.

Source: Tasly Group News